MedPath

The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke

Phase 4
Completed
Conditions
Ischemic Stroke
Interventions
Drug: 0.9% Saline Solution
Registration Number
NCT00868283
Lead Sponsor
Ever Neuro Pharma GmbH
Brief Summary

The study investigated the clinical efficacy and safety of a 10-day course of therapy with daily intravenous administration of 30mL Cerebrolysin based on a comparison with Placebo in patients with acute ischemic stroke. 1070 patients were randomized in this trial in 2 parallel groups, one receiving Cerebrolysin, the control group receiving Placebo. Study drug will be given once daily by intravenous infusion for 10 consecutive days. Acetylsalicylic acid will be given orally, once daily throughout the study duration of 90 days as basic treatment. The clinical observation period for each patient will be 3 months and will include six clinical evaluation visits at Baseline (day 1) and on study days 2, 5, 10, 30 and 90.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1071
Inclusion Criteria
  • Age between 18 and 85 years
  • Focal neurological deficit
  • Clinical diagnosis of acute hemispheric ischemic stroke
  • CT or MRI results compatible with clinical diagnosis of acute hemispheric stroke
  • NIH Stroke Scale Score between 6 and 22, both inclusive
  • Functionally independent prior to stroke with a pre-stroke Rankin Score of 0 or 1
  • Randomization and first treatment with the trial medication within 12h after stroke onset
  • Informed consent given by the patient and/or the patient's legally acceptable representative
Exclusion Criteria
  • Evidence on CT/MRI of acute or chronic intracerebral hemorrhage, SAH, AVM, cerebral aneurysm, or neoplasm
  • Signs of herniation, increased intracranial pressure or likely etiology other than brain ischemia at baseline CT scan
  • Patients with a substantial decrease of consciousness or alertness at the time of randomization, defined as score of 2 or more one of the NIH Stroke Scale questions 1a.
  • Neurological signs and symptoms that improve rapidly during screening and are likely to resolve completely within 24h
  • Severe coexisting systemic disease that significantly limits life expectancy
  • Systolic blood pressure over 220 mmHg or diastolic blood pressure over 120 mmHg on repeated measurement (interval of 30 min) prior to study entry
  • Severe congestive heart failure or presentation with acute myocardial infarction at study entry
  • Epilepsy or epileptic seizures at onset of stroke
  • Pre-existing disorders or conditions that would impair interpretation of neurological assessment (eg. severe dementia, severe psychiatric illnesses, etc).
  • Concomitant treatment with other neuroprotective or nootropic drugs (e.g. piracetam, citicoline, investigational neuroprotective substances)
  • Patients which cannot tolerate or have contraindication to aspirin or Cerebrolysin treatment
  • Concomitant treatment with substances that have a dilative effect on blood vessels like naftidrofuryl, cinnarizine, flunarizine or nimodipine
  • Pregnancy and lactation period; for women with child-bearing potential a negative pregnancy test is required
  • Participation in a clinical trial with an investigational drug in the past 4 weeks

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
0.9% Saline Solution0.9% Saline Solution-
CerebrolysinCerebrolysin-
Primary Outcome Measures
NameTimeMethod
Modified Rankin Scale90 days after start of treatment
Barthel Index90 days after start of treatment
NIH Stroke Scale90 days after start of treatment
Secondary Outcome Measures
NameTimeMethod
SF-1290 days after start of treatment
Overall mortalityThroughout the study

Trial Locations

Locations (49)

Dalian third people Hospital

🇨🇳

Dalian, China

FuJian Shengli Hospital

🇨🇳

Fuzhou, China

The 4st Hospital affiliated Harbin Medical University

🇨🇳

Harbin, China

Union Hospital, affiliated Huazhong science and technology University

🇨🇳

Wuhan, China

East-west neo medical center

🇰🇷

Seoul, Korea, Republic of

First Hospital, affiliated Shantou Medical University

🇨🇳

Guandong, China

First hospital, affiliated NingXia Mededical University

🇨🇳

Yinchuan, China

Asan medical center

🇰🇷

Seoul, Korea, Republic of

Anshan hospital

🇨🇳

Anshan, China

Chengdu 2nd People's Hospital

🇨🇳

Chengdu, China

First Hospital, affiliated Huaxi Medical University

🇨🇳

Chengdu, China

Sichuan Province People's Hospital

🇨🇳

Chengdu, China

Dalian Center Hospital

🇨🇳

Dalian, China

Second Hospital, affiliated Wenzhou Med. University

🇨🇳

Dalian, China

Guangzhou red cross hospital

🇨🇳

Guangzhou, China

Second Hospital, affiliated Kunming Med. University

🇨🇳

Kunming, China

Yinchuan People's Hospital

🇨🇳

Mudanjiang, China

Huashan Hospital, affiliated Fudan University

🇨🇳

Shanghai, China

Ruijin Hospital, affiliated Jiaotong University

🇨🇳

Shanghai, China

Zhongshan Hospital, affiliated Fudan University

🇨🇳

Shanghai, China

Mudanjiang 1st people Hospital

🇨🇳

Mudanjiang, Heilongjiang, China

Anhui Shengli Hospital

🇨🇳

Anhui, China

Third hospital, affiliated Neimenggu Medical University (Bao Gang hospital)

🇨🇳

Baotou, China

Mudanjiang 2nd people Hospital

🇨🇳

Mudanjiang, Heilongjiang, China

Baotou Center Hospital

🇨🇳

Baotou, China

Beijing PLA General Hospital

🇨🇳

Beijing, China

First hospital, affiliated Peking University

🇨🇳

Beijing, China

Friendship Hospital, affiliated Capital Medical University

🇨🇳

Beijing, China

Peking Anzhen Hospital

🇨🇳

Beijing, China

Sino-Japanese Friendship Hospital

🇨🇳

Beijing, China

First hospital, affiliated Bethune Medical University

🇨🇳

Changchun, China

Guangzhou 2nd People's Hospital

🇨🇳

Canton, China

Second Hospital Affiliated Bethune Medical University

🇨🇳

Changchun, China

Xiangya Hospital, affiliated Hunan Medical University

🇨🇳

Changsha, China

Second Hospital, affiliated Chongqing Med. University

🇨🇳

Chongqing, China

First hospital, affiliated Fujian Medical University

🇨🇳

Fuzhou, China

First Hospital, affiliated Medical college Zhejing University

🇨🇳

Hangzhou, China

First Hospital, affiliated Qingdao Medical University

🇨🇳

Qingdao, China

Zhongda Hospital

🇨🇳

Nanjing, China

Renji Hospital, affiliated Second Medical University

🇨🇳

Shanghai, China

Shanghai 6th People's Hospital

🇨🇳

Shanghai, China

Xinhua hospital of Shanghai Jiaotong University School of Medicine

🇨🇳

Shanghai, China

Hebei Province People's Hospital

🇨🇳

Shijiazhuang, China

Tianjin First Medical Center

🇨🇳

Tianjin, China

Tianjin Union Medicine Centre

🇨🇳

Tianjin, China

First hospital, affiliated Henan Medical University

🇨🇳

Zhengzhou, China

Kyung-hee University Hospital

🇰🇷

Seoul, Korea, Republic of

Nanjing PLA General Hospital

🇨🇳

Nanjing, China

Chinese University of Hong Kong

🇭🇰

Hong Kong, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath